Emerging Company Profile
Interline: correcting mutation-induced dysfunctional protein networks
Emerging Company Profile: Interline launches from Foresite Labs with platform to identify and fix altered protein networks in cancer, inflammation
Foresite, Arch provide newly launched Interline with $92 million to develop small molecules to correct mutation-driven dysfunction of protein networks in cancer and inflammatory disease.
May 13, 2021 | 11:38 PM GMT
Interline has launched from Foresite Labs with $92 million in funding